中华皮肤科杂志 ›› 2024, e20230528.doi: 10.35541/cjd.20230528
高金平1 张学军1，2
收稿日期:2023-09-11
修回日期:2024-10-27
发布日期:2024-12-09
通讯作者:
张学军
E-mail:ayzxj@vip.sina.com
Gao Jinping1, Zhang Xuejun1,2
Received:2023-09-11
Revised:2024-10-27
Published:2024-12-09
Contact:
Zhang Xuejun
E-mail:ayzxj@vip.sina.com
摘要： 【摘要】 巴瑞替尼是一种JAK1/JAK2抑制剂，主要用于类风湿性关节炎等免疫炎症性疾病，但其在皮肤病领域中具有一定治疗潜力，已在临床试验中显示出良好的疗效。本文回顾近年来巴瑞替尼在皮肤病治疗领域中的应用，旨在为临床医生提供更加全面的临床用药指导。
高金平 张学军. 巴瑞替尼在皮肤科的临床应用进展[J]. 中华皮肤科杂志, 2024,e20230528. doi:10.35541/cjd.20230528
Gao Jinping, Zhang Xuejun, . Clinical application of baricitinib in dermatology[J]. Chinese Journal of Dermatology,2024,e20230528. doi:10.35541/cjd.20230528
| ［1］ | Banerjee S, Biehl A, Gadina M, et al. JAK⁃STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects［J］. Drugs, 2017,77（5）:521⁃546. doi: 10.1007/s40265⁃017⁃0701⁃9. |
| ［2］ | King B, Ko J, Forman S, et al. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study［J］. J Am Acad Dermatol, 2021,85（4）:847⁃853. doi: 10. 1016/j.jaad.2021.05.050. |
| ［3］ | King B, Ohyama M, Kwon O, et al. Two phase 3 trials of baricitinib for alopecia areata［J］. N Engl J Med, 2022,386（18）:1687⁃1699. doi: 10.1056/NEJMoa2110343. |
| ［4］ | Gupta AK, Wang T, Vincent K, et al. Olumiant® （Baricitinib）⁃a newly approved janus kinase inhibitor for the treatment of alopecia areata［J］. Skinmed, 2022,20（6）:452⁃455. |
| ［5］ | Kwon O, Senna MM, Sinclair R, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 weeks of continuous therapy in two phaseⅢ trials （BRAVE⁃AA1 and BRAVE⁃AA2）［J］. Am J Clin Dermatol, 2023,24（3）:443⁃451. doi: 10.1007/s40257⁃023⁃00764⁃w. |
| ［6］ | Melo A, Carrascosa JM, Torres T. Baricitinib for the treatment of atopic dermatitis［J］. J Dermatolog Treat, 2022,33（5）:2404⁃2413. doi: 10.1080/09546634.2021.1967268. |
| ［7］ | Reich K, DeLozier AM, Nunes FP, et al. Baricitinib improves symptoms in patients with moderate⁃to⁃severe atopic dermatitis and inadequate response to topical corticosteroids: patient⁃reported outcomes from two randomized monotherapy phaseⅢtrials［J］. J Dermatolog Treat, 2022,33（3）:1521⁃1530. doi: 10. 1080/09546634.2020.1839008. |
| ［8］ | Silverberg JI, Simpson EL, Wollenberg A, et al. Long⁃term efficacy of baricitinib in adults with moderate to severe atopic dermatitis who were treatment responders or partial responders: an extension study of 2 randomized clinical trials［J］. JAMA Dermatol, 2021,157（6）:691⁃699. doi: 10.1001/jamadermatol. 2021.1273. |
| ［9］ | Wollenberg A, Lio P, Kleyn E, et al. Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five PhaseⅢ clinical trials［J］. Eur J Dermatol, 2022,32（4）:522⁃529. doi: 10.1684/ejd.2022.4280. |
| ［10］ | Bieber T, Reich K, Paul C, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate⁃to⁃severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo⁃controlled, phaseⅢ clinical trial （BREEZE⁃AD4）［J］. Br J Dermatol, 2022,187（3）:338⁃352. doi: 10.1111/bjd.21630. |
| ［11］ | Wollenberg A, Nakahara T, Maari C, et al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate⁃to⁃severe atopic dermatitis from the BREEZE⁃AD7 phase 3 randomized trial［J］. J Eur Acad Dermatol Venereol, 2021,35（7）:1543⁃1552. doi: 10.1111/jdv.17278. |
| ［12］ | Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase （JAK） 1/JAK2 inhibitor, in patients with moderate⁃to⁃severe psoriasis［J］. Br J Dermatol, 2016,174（6）:1266⁃1276. doi: 10.1111/bjd.14403. |
| ［13］ | Assadiasl S, Fatahi Y, Mosharmovahed B, et al. Baricitinib: from rheumatoid arthritis to COVID⁃19［J］. J Clin Pharmacol, 2021,61（10）:1274⁃1285. doi: 10.1002/jcph.1874. |
| ［14］ | Wallace DJ, Furie RA, Tanaka Y, et al. Baricitinib for systemic lupus erythematosus: a double⁃blind, randomised, placebo⁃controlled, phase 2 trial［J］. Lancet, 2018,392（10143）:222⁃231. doi: 10.1016/S0140⁃6736（18）31363⁃1. |
| ［15］ | Dörner T, van Vollenhoven RF, Doria A, et al. Baricitinib decreases anti⁃dsDNA in patients with systemic lupus erythematosus: results from a phaseⅡ double⁃blind, randomized, placebo⁃controlled trial［J］. Arthritis Res Ther, 2022,24（1）:112. doi: 10.1186/s13075⁃022⁃02794⁃x. |
| ［16］ | Morand EF, Vital EM, Petri M, et al. Baricitinib for systemic lupus erythematosus: a double⁃blind, randomised, placebo⁃controlled, phase 3 trial （SLE⁃BRAVE⁃Ⅰ）［J］. Lancet, 2023,401（10381）:1001⁃1010. doi: 10.1016/S0140⁃6736（22）02607⁃1. |
| ［17］ | Petri M, Bruce IN, Dörner T, et al. Baricitinib for systemic lupus erythematosus: a double⁃blind, randomised, placebo⁃controlled, phase 3 trial （SLE⁃BRAVE⁃Ⅱ）［J］. Lancet, 2023,401（10381）:1011⁃1019. doi: 10.1016/S0140⁃6736（22）02546⁃6. |
| ［18］ | Mumford BP, Gibson A, Chong AH. Repigmentation of vitiligo with oral baricitinib［J］. Australas J Dermatol, 2020,61（4）:374⁃376. doi: 10.1111/ajd.13348. |
| ［19］ | Dong J, Huang X, Ma LP, et al. Baricitinib is effective in treating progressing vitiligo in vivo and in vitro［J］. Dose Response, 2022,20（2）:155932582 21105370. doi: 10.1177/15593258221105370. |
| ［20］ | Li X, Sun Y, Du J, et al. Excellent repigmentation of generalized vitiligo with oral baricitinib combined with NB⁃UVB phototherapy［J］. Clin Cosmet Investig Dermatol, 2023,16:635⁃638. doi: 10. 2147/CCID.S396430. |
| ［21］ | Hou Z, Su X, Han G, et al. JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis［J］. Front Med （Lausanne）, 2022,9:859330. doi: 10.3389/fmed.2022.859330. |
| ［22］ | Fujita Y, Nawata M, Nagayasu A, et al. Fifty⁃two⁃week results of clinical and imaging assessments of a patient with rheumatoid arthritis complicated by systemic sclerosis with interstitial pneumonia and type 1 diabetes despite multiple disease⁃modifying antirheumatic drug therapy that was successfully treated with baricitinib: a novel case report［J］. Case Rep Rheumatol, 2019,2019:5293981. doi: 10.1155/2019/5293981. |
| ［23］ | Boleto G, Cren JB, Avouac J, et al. Successful treatment with baricitinib of refractory arthritis in a patient with severe diffuse cutaneous systemic sclerosis⁃rheumatoid arthritis overlap syndrome［J］. Clin Exp Rheumatol, 2021,39 Suppl 131（4）:163⁃164. doi: 10.55563/clinexprheumatol/gu1ac8. |
| ［24］ | Salz M, Haeberle S, Hoffmann J, et al. Elevated IL⁃31 serum levels in bullous pemphigoid patients correlate with eosinophil numbers and are associated with BP180⁃IgE［J］. J Dermatol Sci, 2017,87（3）:309⁃311. doi: 10.1016/j.jdermsci.2017.07.019. |
| ［25］ | Cornelissen C, Lüscher⁃Firzlaff J, Baron JM, et al. Signaling by IL⁃31 and functional consequences［J］. Eur J Cell Biol, 2012,91（6⁃7）:552⁃566. doi: 10.1016/j.ejcb.2011.07.006. |
| ［26］ | Xiao Y, Xiang H, Li W. Concurrent bullous pemphigoid and plaque psoriasis successfully treated with Janus kinase inhibitor Baricitinib［J］. Dermatol Ther, 2022,35（10）:e15754. doi:10. 1111/dth.15754. |
| ［27］ | You H, Xu D, Zhao J, et al. JAK inhibitors: prospects in connective tissue diseases［J］. Clin Rev Allergy Immunol, 2020,59（3）:334⁃351. doi: 10.1007/s12016⁃020⁃08786⁃6. |
| ［28］ | Kim H, Dill S, O'Brien M, et al. Janus kinase （JAK） inhibition with baricitinib in refractory juvenile dermatomyositis［J］. Ann Rheum Dis, 2021,80（3）:406⁃408. doi: 10.1136/annrheumdis⁃2020⁃218690. |
| ［29］ | Zhao Q, Zhu Z, Fu Q, et al. Baricitinib for the treatment of cutaneous dermatomyositis: a prospective, open⁃label study［J］. J Am Acad Dermatol, 2022,87（6）:1374⁃1376. doi: 10.1016/j.jaad. 2022.08.025. |
| ［30］ | Landon⁃Cardinal O, Guillaume⁃Jugnot P, Toquet S, et al. JAK inhibitors for the treatment of adult dermatomyositis: a pilot study［J］. J Am Acad Dermatol, 2023,88（4）:924⁃926. doi: 10.1016/j.jaad.2022.10.055. |
| ［31］ | Wang Z, Zheng Q, Xuan W, et al. Short⁃term effectiveness of baricitinib in children with refractory and/or severe juvenile dermatomyositis［J］. Front Pediatr, 2022,10:962585. doi: 10. 3389/fped.2022.962585. |
| ［32］ | Mastrolia MV, Orsini SI, Marrani E, et al. Efficacy of Janus kinase inhibitor baricitinib in the treatment of refractory juvenile dermatomyositis complicated by calcinosis［J］. Clin Exp Rheumatol, 2023,41（2）:402⁃403. doi: 10.55563/clinexprheumatol/ 7k9ajj. |
| ［33］ | Karaa S, Cassius C, Jachiet M, et al. Efficacy of Janus kinase 1 and 2 inhibitor baricitinib in multirefractory cutaneous dermatomyositis［J］. Ann Dermatol Venereol, 2023,150（3）:243⁃245. doi: 10.1016/j.annder.2023.03.008. |
| ［34］ | Fischer K, Aringer M, Steininger J, et al. Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib［J］. Br J Dermatol, 2022,187（3）:432⁃435. doi: 10.1111/bjd.21252. |
| ［35］ | Agud⁃Dios M, Arroyo⁃Andres J, Rubio⁃Muñiz C, et al. Juvenile dermatomyositis⁃associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy［J］. Dermatol Ther, 2022,35（12）:e15960. doi: 10.1111/dth.15960. |
| ［36］ | Delvino P, Bartoletti A, Monti S, et al. Successful treatment with baricitinib in a patient with refractory cutaneous dermatomyositis［J］. Rheumatology （Oxford）, 2020,59（12）:4003. doi: 10.1093/rheumatology/keaa377. |
| ［37］ | 中国医疗保健国际交流促进会皮肤科分会, 国家皮肤与免疫疾病临床医学研究中心. 成人皮肌炎诊疗中国专家共识（2022年）［J］. 中华皮肤科杂志, 2022,55（11）:939⁃948. doi: 10.35541/cjd.20220420. |
| ［38］ | Motamed⁃Sanaye A, Khazaee YF, Shokrgozar M, et al. JAK inhibitors in lichen planus: a review of pathogenesis and treatments［J］. J Dermatolog Treat, 2022,33（8）:3098⁃3103. doi: 10.1080/09546634.2022.2116926. |
| ［39］ | Moussa A, Colla T, Morrison B, et al. Effective treatment of oral lichen planus with the JAK inhibitor baricitinib［J］. Australas J Dermatol, 2022,63（2）:276⁃277. doi: 10.1111/ajd.13811. |
| ［40］ | Moussa A, Colla TG, Asfour L, et al. Effective treatment of refractory lichen planus pemphigoides with a Janus kinase⁃1/2 inhibitor［J］. Clin Exp Dermatol, 2022,47（11）:2040⁃2041. doi: 10.1111/ced.15344. |
| ［41］ | Shao S, Tsoi LC, Sarkar MK, et al. IFN⁃γ enhances cell⁃mediated cytotoxicity against keratinocytes via JAK2/STAT1 in lichen planus［J］. Sci Transl Med, 2019,11（511）:eaav7561. doi: 10. 1126/scitranslmed.aav7561. |
| ［42］ | Abduelmula A, Bagit A, Mufti A, et al. The use of Janus kinase inhibitors for lichen planus: an evidence⁃based review［J］. J Cutan Med Surg, 2023,27（3）:271⁃276. doi: 10.1177/1203475 4231156100. |
| ［43］ | Nash P, Kerschbaumer A, Dörner T, et al. Points to consider for the treatment of immune⁃mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement［J］. Ann Rheum Dis, 2021,80（1）:71⁃87. doi: 10.1136/annrheumdis⁃2020⁃21 8398. |
| [1] | 艾芳婷 孙紫君 苗国英 姚春霞. 钙敏感受体在老年皮肤病理生理中的作用研究进展[J]. 中华皮肤科杂志, 2025, 58(1): 76-79. |
| [2] | 张嘉琪 吴凡 韩雨晴 刘琦 盘瑶. 多光子显微镜在皮肤科中的应用[J]. 中华皮肤科杂志, 2024, 57(9): 857-862. |
| [3] | 邹先彪 陈锦纯 曾悦 郝轶. [开放获取] 超声检查在皮肤科的应用前景[J]. 中华皮肤科杂志, 2024, 57(9): 785-790. |
| [4] | 曾悦 邵惠红 林诗雯 温柔 邹先彪. 可穿戴远程会诊设备在常见皮肤病诊断中的应用[J]. 中华皮肤科杂志, 2024, 57(9): 797-800. |
| [5] | 郝峰 刘国艳. [开放获取] 光学相干断层扫描技术在皮肤科的应用进展[J]. 中华皮肤科杂志, 2024, 57(9): 853-857. |
| [6] | 程锐璇 张春兰 段大威 臧丹丹 杜鑫 王峰. 补体调节蛋白CD55和CD59在Stevens-Johnson综合征/中毒性表皮坏死松解症患者外周血的表达水平[J]. 中华皮肤科杂志, 2024, 57(8): 715-720. |
| [7] | 林子沅 庞天怡 武静文 靳慧. 多环芳烃在炎症性皮肤病发生发展中的作用研究进展[J]. 中华皮肤科杂志, 2024, 57(8): 765-769. |
| [8] | 王晨 薛晨红 宋静卉 李建国 李振鲁 张守民 李明 王建波. 阿达木单抗治疗Blau综合征1家系3例[J]. 中华皮肤科杂志, 2024, 57(6): 553-556. |
| [9] | 荆可 李锁 冯素英. 线状IgA大疱性皮病26例临床及免疫血清学特征回顾分析[J]. 中华皮肤科杂志, 2024, 57(6): 503-509. |
| [10] | 韩燕 徐鹏 向志 姜婷婷 葛凤琴 尹跃平 陈祥生. [开放获取] 加强慢性皮肤病的防治研究——群医学研究计划[J]. 中华皮肤科杂志, 2024, 57(6): 567-569. |
| [11] | 胡梦瑶 李敏 陈思涵 魏雪翠 陈宇杰 徐松 陈旭. 角质形成细胞表达的S100A8/A9在3种常见皮肤炎症损伤模式中调控效应差异的研究[J]. 中华皮肤科杂志, 2024, 57(5): 435-444. |
| [12] | 赵迎 高翠娥 隋昕 宋志强. 基于高加索人单细胞转录组的炎症性树突状表皮细胞的免疫代谢研究[J]. 中华皮肤科杂志, 2024, 57(4): 343-349. |
| [13] | 周甜甜 吴雪歌 杨欢 方晓 蒋金秋 陈静思 罗晓燕 王华. 儿童慢性自发性荨麻疹病因及严重程度相关因素分析[J]. 中华皮肤科杂志, 2024, 57(4): 324-330. |
| [14] | 裴璐 郑娜娜 曾荣 谢媛媛 徐浩翔 段志敏 刘宇甄 李岷. 痤疮丙酸杆菌生物膜诱导角质形成细胞发生炎症反应的分子机制研究[J]. 中华皮肤科杂志, 2024, 57(4): 302-308. |
| [15] | 洪永镇 王倩 梁俊琴. 二代测序技术在非遗传性皮肤病领域中的运用[J]. 中华皮肤科杂志, 2024, 0(3): 20220436-e20220436. |
|
